Restoring sulfide-mediated protective metabolism in metabolic disease and myopathies
¶¶Òõapp Therapeutics
¶¶Òõapp Therapeutics' first-in-class first-in-mechanism mitochondriotropic platform has the potential to address some of the most challenging diseases, focusing initially on obesity-related indications and myopathies, and expandable to broad additional areas of medicine. ¶¶Òõapp’s restoration-of-function the sulfide-signaling system in metabolic disease models has been independently demonstrated to be both anti-obesogenic and muscle-protective.
Based in Oxford and Exeter, UK, ¶¶Òõapp is developing a pipeline of pre-clinical programs to progress to the clinic. Built around the pioneer of mitochondrial-targeted sulfide donor technology, Prof Matt Whiteman PhD, the team is highly skilled in small molecule drug discovery and development as well as IP strategy.
¶¶Òõapp Therapeutics' mtH2SD technology is based on over a decade’s work, and over twenty publications demonstrating pharmacological utility of mitochondrial-targeted sulfide donors in multiple in vivo models.
Multiple peer-reviewed publications since 2014 have proven beyond a doubt that trans-sulfuration dysfunction is a feature of several progressive metabolic diseases, myopathies, lung inflammatory disease and rare indications as part of a shared pathophysiology preventing escape from mitochondrial dysfunction.
¶¶Òõapp Therapeutics mtH2SD approach reverses such mitochondrial dysfunction, enabling us to overcome mitochondrial-driven disease states which lead to muscle weakness, muscle wasting, cognitive deficit and neurodegeneration.
- Professor Matt Whiteman PhD, CSO
°¿±«¸éÌý²õ³¦¾±±ð²Ô³¦±ð
The ideal mitochondrial medicine mechanism of action should:
• Restore mitochondrial function by modulating key mitochondrial metabolic transactivators which are under-activated in the target disease
â€
• Simultaneously act at epigenetic, transcriptional and post-translational levels
• Be subject to safe enzymatic release within the mitochondria, avoiding rapid, abiotic or systemic releaseâ€
¶¶Òõapp Therapeutics' proprietary technology exploits an endogenous mechanism which mediates sulfide-signaling, having the effect of substrate replenishment in states of trans-sulfuration deficiency omnipresent in several diseases and certain medical conditions, resulting in the restoration of adaptive metabolism.
â€
While sulfide is rapidly metabolised, our products are potent and highly targeted, resulting in small and safe doses.
Disclosed Pipeline
Work with us
¶¶Òõapp's pioneering new modality is the first potential medicine to functionally restore sulfide-signaling, which is mediated by the S-persulfidation post-translational modification of proteins. Our approach offers the opportunity to restore essential signaling events needed for protective metabolism to halt or reverse progression in multiple diseases where such sulfide-signaling impairment drives pathophysiology.
There are research collaboration and partnering opportunities in our core programs in obesity-related indication and Duchenne muscular dystrophy, with additional opportunities in the lung inflammatory diseases including IPF, CBS-deficiency and neurodegenerative disease including Parkinson's disease, Alzheimer's disease and Huntington's disease, as well as prevention of muscle wasting in sarcopenia, cancer cachexia and COPD cachexia.
our talents
¶¶Òõapp Therapeutics' mission is to arrest or profoundly delay progressive diseases featurin